A novel fixed-combination timolol-netarsudil-latanoprost ophthalmic solution for the treatment of glaucoma and ocular hypertension.

Wang, Tao; Zhang, Yunran; Chi, Meiling; Zhao, Chen; Cao, Linlin; Tian, Chutong; Kamei, K; Zheng, Ying; Jiang, Qikun.

Afiliação

Wang T; Department of Pharmaceutics, Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China.
Zhang Y; Department of Pharmaceutics, Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China.
Chi M; Changzhou pharmaceutical factory co. LTD, Jiangsu 213000, China.
Zhao C; Department of Pharmaceutics, Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China.
Cao L; Department of Pharmaceutics, Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China.
Tian C; Department of Pharmaceutics, The Second Hospital of Dalian Medical University, Dalian 116023, China.
Kamei K; Department of Pharmaceutics, Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China.
Zheng Y; Department of Pharmaceutics, Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China.
Jiang Q; State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macau, China.

Asian J Pharm Sci ; 17(6): 938-948, 2022 Nov.

Article em En | MEDLINE | ID: mdl-36600899

Palavras-chave

Fixed-combination timolol-netarsudil-latanoprost ophthalmic solution; Glaucoma; Homologous salt engineering strategy; Intraocular pressure; Timolol mesylate

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2022 Tipo de documento: Article